8. Cell Therapeutics ( CTICD) Company Profile: Cell Therapeutics is a biopharmaceutical company with a focus on oncology. Last month, TheStreet's Adam Feuerstein reported that the Food and Drug Administration had again rejected pixantrone, which is Cell Therapeutics' treatment for non-Hodgkin's lymphoma. Altman Z-score: -37.19 Current Share Price: $2.19 (June 7) 2011 Return: The stock is unchanged this year. Current Ratio: 1.20, indicating that Cell Therapeutics should be able to meet its short-term liabilities with its current assets.